Pancreatic cancer

The Lancet

Volumn 388, Issue 10039, 2016, Pages 73-85

  Kamisawa, Terumi ^a   Wood, Laura D ^b   Itoi, Takao ^c   Takaori, Kyoichi ^d  

^a TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c TOKYO MEDICAL UNIVERSITY   (Japan)

^d KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CA 125 ANTIGEN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CONKO 001; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; IRINOTECAN; LAMININ GAMMA C; MEMBRANE PROTEIN; OXALIPLATIN; PACLITAXEL; UNCLASSIFIED DRUG; 130-NM ALBUMIN-BOUND PACLITAXEL; ALBUMINOID; CAMPTOTHECIN; DEOXYCYTIDINE; KRAS PROTEIN, HUMAN; PLATINUM COMPLEX; PROTEIN P21; PROTEIN P53; SMAD4 PROTEIN; SMAD4 PROTEIN, HUMAN; TP53 PROTEIN, HUMAN;

ADJUVANT THERAPY; ADVANCED CANCER; AUTOIMMUNE PANCREATITIS; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL TRIAL (TOPIC); ECHOGRAPHY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; ENDOSCOPIC ULTRASONOGRAPHY; HISTOPATHOLOGY; HUMAN; META ANALYSIS (TOPIC); MOLECULAR PATHOLOGY; MULTIDETECTOR COMPUTED TOMOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS CANCER; PHASE 3 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW (TOPIC); ANALOGS AND DERIVATIVES; CARCINOMA, PANCREATIC DUCTAL; ENDOSCOPIC ULTRASOUND GUIDED FINE NEEDLE BIOPSY; GENETICS; METABOLISM; NEOPLASMS, CYSTIC, MUCINOUS, AND SEROUS; PANCREAS RESECTION; PANCREATIC NEOPLASMS; TUMOR SUPPRESSOR GENE;

ALBUMINS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CA-19-9 ANTIGEN; CAMPTOTHECIN; CARCINOEMBRYONIC ANTIGEN; CARCINOMA, PANCREATIC DUCTAL; DEOXYCYTIDINE; ENDOSCOPIC ULTRASOUND-GUIDED FINE NEEDLE ASPIRATION; ENDOSONOGRAPHY; FLUOROURACIL; GENES, P16; HUMANS; LEUCOVORIN; NEOPLASMS, CYSTIC, MUCINOUS, AND SEROUS; ORGANOPLATINUM COMPOUNDS; PACLITAXEL; PANCREATECTOMY; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS P21(RAS); SMAD4 PROTEIN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84961813357     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(16)00141-0     Document Type: Review

References (116)

1. 1 Siegel, R, Ma, J, Zou, Z, et al. Cancer statistics, 2014. CA Cancer J Clin 64 (2014), 9–29.
2. 2 Gillen, S, Schuster, T, Meyer Zum Büschenfelde, C, et al. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med, 7, 2010, e1000267.
3. 3 Kamisawa, T, Isawa, T, Koike, M, et al. Hematogenous metastases of pancreatic ductal carcinoma. Pancreas 11 (1995), 345–349.
4. 4 Hruban, RH, Canto, MI, Goggins, M, et al. Update on familial pancreatic cancer. Adv Surg 44 (2010), 293–311.
5. 5 Iodice, S, Gandini, S, Maisonneuve, P, et al. Tobacco and the risk of pancreatic cancer: a review and meta-analysis. Langenbecks Arch Surg 393 (2008), 535–545.
6. 6 Raimondi, S, Lowenfels, AB, Morselli-Labate, AM, et al. Pancreatic cancer in chronic pancreatitis; aetiology, incidence, and early detection. Best Pract Res Clin Gastroenterol 24 (2010), 349–358.
7. 7 Bosetti, C, Rosato, V, Li, D, et al. Diabetes, antidiabetic medications, and pancreatic cancer risk: an analysis from the International Pancreatic Cancer Case-Control Consortium. Ann Oncol 25 (2014), 2065–2072.
8. 8 Sah, RP, Nagpal, SJS, Mukhopadhyay, D, et al. New insights into pancreatic cancer-induced paraneoplastic diabetes. Nat Rev Gastroenterol Hepatol 10 (2013), 423–433.
9. 9 Rahib, L, Smith, BD, Aizenberg, R, et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 74 (2014), 2913–2921.
10. 10 Malvezzi, M, Bertuccio, P, Levi, F, et al. European cancer mortality predictions for the year 2014. Ann Oncol 25 (2014), 1650–1656.
11. 11 Hruban, RH, Boffetta, P, Hiraoka, N, et al. Ductal adenocarcinoma of the pancreas. Hruban, RH, Hiraoka, N, Iacobuzio-Donahue, C, Bosman, FTJ, Lakhani, SR, Ohgaki, H, et al. (eds.) WHO classification of tumours of the digestive system. WHO classification of tumours, 4th edn., 2010, International Agency for Research on Cancer, Lyon, 281–291.
12. 12 Chang, KJ, Parasher, G, Christie, C, et al. Risk of pancreatic adenocarcinoma: disparity between African Americans and other race/ethnic groups. Cancer 103 (2005), 349–357.
13. 13 Silverman, DT, Hoover, RN, Brown, LM, et al. Why do black Americans have a higher risk of pancreatic cancer than white Americans?. Epidemiology 14 (2003), 45–54.
14. 14 Klein, AP, Brune, KA, Petersen, GM, et al. Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res 64 (2004), 2634–2638.
15. 15 Solomon, S, Das, S, Brand, R, et al. Inherited pancreatic cancer syndromes. Cancer J 18 (2012), 485–491.
16. 16 Rustgi, AK, Familial pancreatic cancer: genetic advances. Genes Dev 28 (2014), 1–7.
17. 17 Couch, FJ, Johnson, MR, Rabe, KG, et al. The prevalence of BRCA2 mutations in familial pancreatic cancer. Cancer Epidemiol Biomarkers Prev 16 (2007), 342–346.
18. 18 Goldstein, AM, Fraser, MC, Struewing, JP, et al. Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. N Engl J Med 333 (1995), 970–974.
19. 19 Giardiello, FM, Welsh, SB, Hamilton, SR, et al. Increased risk of cancer in the Peutz-Jeghers syndrome. N Engl J Med 316 (1987), 1511–1514.
20. 20 Lowenfels, AB, Maisonneuve, P, DiMagno, EP, et al., the International Hereditary Pancreatitis Study Group. Hereditary pancreatitis and the risk of pancreatic cancer. J Natl Cancer Inst 89 (1997), 442–446.
21. 21 McWilliams, RR, Petersen, GM, Rabe, KG, et al. Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations and risk for pancreatic adenocarcinoma. Cancer 116 (2010), 203–209.
22. 22 Kastrinos, F, Mukherjee, B, Tayob, N, et al. Risk of pancreatic cancer in families with Lynch syndrome. JAMA 302 (2009), 1790–1795.
23. 23 Jones, S, Hruban, RH, Kamiyama, M, et al. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science, 324, 2009, 217.
24. 24 Roberts, NJ, Jiao, Y, Yu, J, et al. ATM mutations in patients with hereditary pancreatic cancer. Cancer Discov 2 (2012), 41–46.
25. 25 Arslan, AA, Helzlsouer, KJ, Kooperberg, C, et al., the Pancreatic Cancer Cohort Consortium (PanScan). Anthropometric measures, body mass index, and pancreatic cancer: a pooled analysis from the Pancreatic Cancer Cohort Consortium (PanScan). Arch Intern Med 170 (2010), 791–802.
26. 26 Fukushima, N, Hruban, RH, Kato, Y, et al. Ductal adenocarcinoma variants and mixed neoplasms of the pancreas. Fukushima, N, Klimstra, DS, Kloppel, G, Bosman, FTJ, Lakhani, SR, Ohgaki, H, et al. (eds.) WHO classification of tumours of the digestive system. WHO classification of tumours, 4th edn., 2010, International Agency for Research on Cancer, Lyon, 292–295.
27. 27 Tomlinson, JS, Jain, S, Bentrem, DJ, et al. Accuracy of staging node-negative pancreas cancer: a potential quality measure. Arch Surg 142 (2007), 767–823 discussion 773–74.
28. 28 Hruban, RH, Adsay, NV, Albores-Saavedra, J, et al. Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions. Am J Surg Pathol 25 (2001), 579–586.
29. 29 Basturk, O, Hong, SM, Wood, LD, et al. A Revised classification system and recommendations from the Baltimore consensus meeting for neoplastic precursor lesions in the pancreas. Am J Surg Pathol 39 (2015), 1730–1741.
30. 30 Adsay, NV, Fukushima, N, Furukawa, T, et al. Intraductal neoplasms of the pancreas. Adsay, NV, Furukawa, T, Hruban, RH, Bosman, FTJ, Lakhani, SR, Ohgaki, H, et al. (eds.) WHO classification of tumours of the digestive system. WHO classification of tumours, 4th edn., 2010, International Agency for Research on Cancer, Lyon, 304–313.
31. 31 Furukawa, T, Klöppel, G, Volkan Adsay, N, et al. Classification of types of intraductal papillary-mucinous neoplasm of the pancreas: a consensus study. Virchows Arch 447 (2005), 794–799.
32. 32 Zamboni, G, Fukushima, N, Hruban, RH, et al. Mucinous cystic neoplasms of the pancreas. Zamboni, G, Hruban, RH, Kloppel, G, Bosman, FTJ, Lakhani, SR, Ohgaki, H, et al. (eds.) WHO classification of tumours of the digestive system. WHO classification of tumours, 4th edn., 2010, International Agency for Research on Cancer, Lyon, 300–303.
33. 33 Vogelstein, B, Papadopoulos, N, Velculescu, VE, et al. Cancer genome landscapes. Science 339 (2013), 1546–1558.
34. 34 Wood, LD, Hruban, RH, Pathology and molecular genetics of pancreatic neoplasms. Cancer J 18 (2012), 492–501.
35. 35 Jones, S, Zhang, X, Parsons, DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321 (2008), 1801–1806.
36. 36 Biankin, AV, Waddell, N, Kassahn, KS, et al., the Australian Pancreatic Cancer Genome Initiative. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 491 (2012), 399–405.
37. 37 Waddell, N, Pajic, M, Patch, AM, et al., the Australian Pancreatic Cancer Genome Initiative. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 518 (2015), 495–501.
38. 38 Kanda, M, Matthaei, H, Wu, J, et al. Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia. Gastroenterology 142 (2012), 730–733.
39. 39 Maitra, A, Adsay, NV, Argani, P, et al. Multicomponent analysis of the pancreatic adenocarcinoma progression model using a pancreatic intraepithelial neoplasia tissue microarray. Mod Pathol 16 (2003), 902–912.
40. 40 Murphy, SJ, Hart, SN, Lima, JF, et al. Genetic alterations associated with progression from pancreatic intraepithelial neoplasia to invasive pancreatic tumor. Gastroenterology 145 (2013), 1098–1109.
41. 41 Wu, J, Jiao, Y, Dal Molin, M, et al. Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways. Proc Natl Acad Sci USA 108 (2011), 21188–21193.
42. 42 Wu, J, Matthaei, H, Maitra, A, et al. Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. Sci Transl Med, 3, 2011, 92ra66.
43. 43 Keane, MG, Horsfall, L, Rait, G, et al. A case-control study comparing the incidence of early symptoms in pancreatic and biliary tract cancer. BMJ Open, 4, 2014, e005720.
44. 44 Cosci, F, Fava, GA, Sonino, N, Mood and anxiety disorders as early manifestations of medical illness: a systematic review. Psychother Psychosom 84 (2015), 22–29.
45. 45 Sharma, C, Eltawil, KM, Renfrew, PD, et al. Advances in diagnosis, treatment and palliation of pancreatic carcinoma: 1990-2010. World J Gastroenterol 17 (2011), 867–897.
46. 46 Li, J, Li, Y, Cao, G, et al. Early manifestations of pancreatic cancer: the effect of cancer-nerve interaction. Med Hypotheses 81 (2013), 180–182.
47. 47 Grahm, AL, Andrén-Sandberg, A, Prospective evaluation of pain in exocrine pancreatic cancer. Digestion 58 (1997), 542–549.
48. 48 Ni, XG, Bai, XF, Mao, YL, et al. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer. Eur J Surg Oncol 31 (2005), 164–169.
49. 49 Safi, F, Schlosser, W, Kolb, G, et al. Diagnostic value of CA 19-9 in patients with pancreatic cancer and nonspecific gastrointestinal symptoms. J Gastrointest Surg 1 (1997), 106–112.
50. 50 Goonetilleke, KS, Siriwardena, AK, Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol 33 (2007), 266–270.
51. 51 Gattani, AM, Mandeli, J, Bruckner, HW, Tumor markers in patients with pancreatic carcinoma. Cancer 78 (1996), 57–62.
52. 52 Chan, A, Prassas, I, Dimitromanolakis, A, et al. Validation of biomarkers that complement CA19.9 in detecting early pancreatic cancer. Clin Cancer Res 20 (2014), 5787–5795.
53. 53 O'Brien, DP, Sandanayake, NS, Jenkinson, C, et al. Serum CA19-9 is significantly upregulated up to 2 years before diagnosis with pancreatic cancer: implications for early disease detection. Clin Cancer Res 21 (2015), 622–631.
54. 54 Conrad, C, Fernández-Del Castillo, C, Preoperative evaluation and management of the pancreatic head mass. J Surg Oncol 107 (2013), 23–32.
55. 55 Fan, Z, Li, Y, Yan, K, et al. Application of contrast-enhanced ultrasound in the diagnosis of solid pancreatic lesions–a comparison of conventional ultrasound and contrast-enhanced CT. Eur J Radiol 82 (2013), 1385–1390.
56. 56 Zhang, Y, Huang, J, Chen, M, et al. Preoperative vascular evaluation with computed tomography and magnetic resonance imaging for pancreatic cancer: a meta-analysis. Pancreatology 12 (2012), 227–233.
57. 57 Ahn, SS, Kim, MJ, Choi, JY, et al. Indicative findings of pancreatic cancer in prediagnostic CT. Eur Radiol 19 (2009), 2448–2455.
58. 58 Diehl, SJ, Lehmann, KJ, Sadick, M, et al. Pancreatic cancer: value of dual-phase helical CT in assessing resectability. Radiology 206 (1998), 373–378.
59. 59 Lu, DS, Reber, HA, Krasny, RM, et al. Local staging of pancreatic cancer: criteria for unresectability of major vessels as revealed by pancreatic-phase, thin-section helical CT. AJR Am J Roentgenol 168 (1997), 1439–1443.
60. 60 Wang, Z, Chen, JQ, Liu, JL, et al. FDG-PET in diagnosis, staging and prognosis of pancreatic carcinoma: a meta-analysis. World J Gastroenterol 19 (2013), 4808–4817.
61. 61 Rijkers, AP, Valkema, R, Duivenvoorden, HJ, et al. Usefulness of F-18-fluorodeoxyglucose positron emission tomography to confirm suspected pancreatic cancer: a meta-analysis. Eur J Surg Oncol 40 (2014), 794–804.
62. 62 Tang, S, Huang, G, Liu, J, et al. Usefulness of 18F-FDG PET, combined FDG-PET/CT and EUS in diagnosing primary pancreatic carcinoma: a meta-analysis. Eur J Radiol 78 (2011), 142–150.
63. 63 Park, HS, Lee, JM, Choi, HK, et al. Preoperative evaluation of pancreatic cancer: comparison of gadolinium-enhanced dynamic MRI with MR cholangiopancreatography versus MDCT. J Magn Reson Imaging 30 (2009), 586–595.
64. 64 Balci, NC, Perman, WH, Saglam, S, et al. Diffusion-weighted magnetic resonance imaging of the pancreas. Top Magn Reson Imaging 20 (2009), 43–47.
65. 65 Fattahi, R, Balci, NC, Perman, WH, et al. Pancreatic diffusion-weighted imaging (DWI): comparison between mass-forming focal pancreatitis (FP), pancreatic cancer (PC), and normal pancreas. J Magn Reson Imaging 29 (2009), 350–356.
66. 66 Takeuchi, M, Matsuzaki, K, Kubo, H, et al. High-b-value diffusion-weighted magnetic resonance imaging of pancreatic cancer and mass-forming chronic pancreatitis: preliminary results. Acta Radiol 49 (2008), 383–386.
67. 67 Sandrasegaran, K, Nutakki, K, Tahir, B, et al. Use of diffusion-weighted MRI to differentiate chronic pancreatitis from pancreatic cancer. AJR Am J Roentgenol 201 (2013), 1002–1008.
68. 68 Maccioni, F, Martinelli, M, Al Ansari, N, et al. Magnetic resonance cholangiography: past, present and future: a review. Eur Rev Med Pharmacol Sci 14 (2010), 721–725.
69. 69 Yamaguchi, T, Shirai, Y, Nakamura, N, et al. Usefulness of brush cytology combined with pancreatic juice cytology in the diagnosis of pancreatic cancer: significance of pancreatic juice cytology after brushing. Pancreas 41 (2012), 1225–1229.
70. 70 Mikata, R, Ishihara, T, Tada, M, et al. Clinical usefulness of repeated pancreatic juice cytology via endoscopic naso-pancreatic drainage tube in patients with pancreatic cancer. J Gastroenterol 48 (2013), 866–873.
71. 71 Meining, A, Shah, RJ, Slivka, A, et al. Classification of probe-based confocal laser endomicroscopy findings in pancreaticobiliary strictures. Endoscopy 44 (2012), 251–257.
72. 72 Agarwal, B, Abu-Hamda, E, Molke, KL, et al. Endoscopic ultrasound-guided fine needle aspiration and multidetector spiral CT in the diagnosis of pancreatic cancer. Am J Gastroenterol 99 (2004), 844–850.
73. 73 DeWitt, J, Devereaux, B, Chriswell, M, et al. Comparison of endoscopic ultrasonography and multidetector computed tomography for detecting and staging pancreatic cancer. Ann Intern Med 141 (2004), 753–763.
74. 74 Gong, TT, Hu, DM, Zhu, Q, Contrast-enhanced EUS for differential diagnosis of pancreatic mass lesions: a meta-analysis. Gastrointest Endosc 76 (2012), 301–309.
75. 75 Bang, JY, Magee, SH, Ramesh, J, et al. Randomized trial comparing fanning with standard technique for endoscopic ultrasound-guided fine-needle aspiration of solid pancreatic mass lesions. Endoscopy 45 (2013), 445–450.
76. 76 Nakai, Y, Isayama, H, Chang, KJ, et al. Slow pull versus suction in endoscopic ultrasound-guided fine-needle aspiration of pancreatic solid masses. Dig Dis Sci 59 (2014), 1578–1585.
77. 77 Attam, R, Arain, MA, Bloechl, SJ, et al. “Wet suction technique (WEST)”: a novel way to enhance the quality of EUS-FNA aspirate. Results of a prospective, single-blind, randomized, controlled trial using a 22-gauge needle for EUS-FNA of solid lesions. Gastrointest Endosc 81 (2015), 1401–1407.
78. 78 Qin, SY, Zhou, Y, Li, P, Jiang, HX, Diagnostic efficacy of cell block immunohistochemistry, smear cytology, and liquid-based cytology in endoscopic ultrasound-guided fine-needle aspiration of pancreatic lesions: a single-institution experience. PLoS One, 9, 2014, e108762.
79. 79 Brand, RE, Adai, AT, Centeno, BA, et al. A microRNA-based test improves endoscopic ultrasound-guided cytologic diagnosis of pancreatic cancer. Clin Gastroenterol Hepatol 12 (2014), 1717–1723.
80. 80 Jabbar, KS, Verbeke, C, Hyltander, AG, et al. Proteomic mucin profiling for the identification of cystic precursors of pancreatic cancer. J Natl Cancer Inst, 106, 2014, djt439.
81. 81 Fuccio, L, Hassan, C, Laterza, L, et al. The role of K-ras gene mutation analysis in EUS-guided FNA cytology specimens for the differential diagnosis of pancreatic solid masses: a meta-analysis of prospective studies. Gastrointest Endosc 78 (2013), 596–608.
82. 82 Kamisawa, T, Zen, Y, Pillai, S, et al. IgG4-related disease. Lancet 385 (2015), 1460–1471.
83. 83 Kamisawa, T, Imai, M, Yui Chen, P, et al. Strategy for differentiating autoimmune pancreatitis from pancreatic cancer. Pancreas 37 (2008), e62–e67.
84. 84 Shimosegawa, T, Chari, ST, Frulloni, L, et al., the International Association of Pancreatology. International consensus diagnostic criteria for autoimmune pancreatitis: guidelines of the International Association of Pancreatology. Pancreas 40 (2011), 352–358.
85. 85 Tanaka, M, Fernández-del Castillo, C, Adsay, V, et al., the International Association of Pancreatology. International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology 12 (2012), 183–197.
86. 86 Callery, MP, Chang, KJ, Fishman, EK, et al. Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann Surg Oncol 16 (2009), 1727–1733.
87. 87 Bockhorn, M, Uzunoglu, FG, Adham, M, et al., the International Study Group of Pancreatic Surgery. Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS). Surgery 155 (2014), 977–988.
88. 88 He, J, Page, AJ, Weiss, M, et al. Management of borderline and locally advanced pancreatic cancer: where do we stand?. World J Gastroenterol 20 (2014), 2255–2266.
89. 89 Van Laethem, JL, Verslype, C, Iovanna, JL, et al., the European Society for Medical Oncology. New strategies and designs in pancreatic cancer research: consensus guidelines report from a European expert panel. Ann Oncol 23 (2012), 570–576.
90. 90 Evans, DB, Farnell, MB, Lillemoe, KD, et al. Surgical treatment of resectable and borderline resectable pancreas cancer: expert consensus statement. Ann Surg Oncol 16 (2009), 1736–1744.
91. 91 Nimura, Y, Nagino, M, Takao, S, et al. Standard versus extended lymphadenectomy in radical pancreatoduodenectomy for ductal adenocarcinoma of the head of the pancreas: long-term results of a Japanese multicenter randomized controlled trial. J Hepatobiliary Pancreat Sci 19 (2012), 230–241.
92. 92 Jang, JY, Kang, MJ, Heo, JS, et al. A prospective randomized controlled study comparing outcomes of standard resection and extended resection, including dissection of the nerve plexus and various lymph nodes, in patients with pancreatic head cancer. Ann Surg 259 (2014), 656–664.
93. 93 Shin, SH, Kim, SC, Song, KB, et al. A comparative study of laparoscopic vs. open distal pancreatectomy for left-sided ductal adenocarcinoma: a propensity score-matched analysis. J Am Coll Surg 220 (2015), 177–185.
94. 94 Mesleh, MG, Stauffer, JA, Asbun, HJ, Minimally invasive surgical techniques for pancreatic cancer: ready for prime time?. J Hepatobiliary Pancreat Sci 20 (2013), 578–582.
95. 95 Begg, CB, Cramer, LD, Hoskins, WJ, et al. Impact of hospital volume on operative mortality for major cancer surgery. JAMA 280 (1998), 1747–1751.
96. 96 Vincent, A, Herman, J, Schulick, R, et al. Pancreatic cancer. Lancet 378 (2011), 607–620.
97. 97 Neoptolemos, JP, Stocken, DD, Friess, H, et al., the European Study Group for Pancreatic Cancer. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 350 (2004), 1200–1210.
98. 98 Oettle, H, Neuhaus, P, Hochhaus, A, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA 310 (2013), 1473–1481.
99. 99 Maeda, A, Boku, N, Fukutomi, A, et al. Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 in patients with resected pancreatic cancer: Japan Adjuvant Study Group of Pancreatic Cancer (JASPAC-01). Jpn J Clin Oncol 38 (2008), 227–229.
100. 100 Sudo, K, Nakamura, K, Yamaguchi, T, S-1 in the treatment of pancreatic cancer. World J Gastroenterol 20 (2014), 15110–15118.
101. 101 Burris, HA 3rd, Moore, MJ, Andersen, J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15 (1997), 2403–2413.
102. 102 Moore, MJ, Goldstein, D, Hamm, J, et al., the National Cancer Institute of Canada Clinical Trials Group. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25 (2007), 1960–1966.
103. 103 Conroy, T, Desseigne, F, Ychou, M, et al. the Groupe Tumeurs Digestives of Unicancer, the PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364 (2011), 1817–1825.
104. 104 Von Hoff, DD, Ervin, T, Arena, FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369 (2013), 1691–1703.
105. 105 Pelzer, U, Schwaner, I, Stieler, J, et al. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur J Cancer 47 (2011), 1676–1681.
106. 106 Huguet, F, Girard, N, Guerche, CS, et al. Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic review. J Clin Oncol 27 (2009), 2269–2277.
107. 107 Loehrer, PJ Sr, Feng, Y, Cardenes, H, et al. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol 29 (2011), 4105–4112.
108. 108 Philip, PA, Locally advanced pancreatic cancer: where should we go from here?. J Clin Oncol 29 (2011), 4066–4068.
109. 109 Takaori, K, Bassi, C, Biankin, A, et al. International Association of Pancreatology (IAP)/European Pancreatic Club (EPC) consensus review of guidelines for the treatment of pancreatic cancer. Pancreatology, 2015, 10.1016/j.pan.2015.10.013 published online Nov 12.
110. 110 Soderlund, C, Linder, S, Covered metal versus plastic stents for malignant common bile duct stenosis: a prospective, randomized, controlled trial. Gastrointest Endosc 63 (2006), 986–995.
111. 111 Canto, MI, Harinck, F, Hruban, RH, et al., the International Cancer of Pancreas Screening (CAPS) Consortium. International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut 62 (2013), 339–347.
112. 112 Chantrill, LA, Nagrial, AM, Watson, C, et al. the Australian Pancreatic Cancer Genome Initiative (APGI), the Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial Management Committee of the Australasian Gastrointestinal Trials Group (AGITG). Precision medicine for advanced pancreas cancer: the Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial. Clin Cancer Res 21 (2015), 2029–2037.
113. 113 Deeks, ED, Olaparib: first global approval. Drugs 75 (2015), 231–240.
114. 114 Yamaue, H, Tsunoda, T, Tani, M, et al. Randomized phase II/III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS-PC Study. Cancer Sci 106 (2015), 883–890.
115. 115 Lutz, ER, Wu, AA, Bigelow, E, et al. Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation. Cancer Immunol Res 2 (2014), 616–631.
116. 116 Stromnes, IM, DelGiorno, KE, Greenberg, PD, et al. Stromal reengineering to treat pancreas cancer. Carcinogenesis 35 (2014), 1451–1460.